Retrovir efficacy supplement approved.
D000284:Administration, Oral; D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002214:Capsules; D002648:Child; D002675:Child, Preschool; D004304:Dosage Forms; D017277:Drug Approval; D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007223:Infant; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000008:administration & dosage* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002214:Capsules; D004304:Dosage Forms; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D015215:Zidovudine